Pevonedistat
Small molecule targets MCL1 via inhibition
Trials 41
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2021-09-01 | Takeda | Results Takeda Provides Update on Phase 3 PANTHER (Pevonedistat-3001) Trial takeda.com ↗
Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (“Takeda”) today announced that the Phase 3 PANTHER (Pevonedistat-3001) study did not achieve pre-defined statistical significance for the primary endpoint of event-free survival (EFS). |
| 2020-11-05 | Takeda | Results Takeda Oncology Demonstrates Leadership in Hematologic Cancers at 62nd American Society of Hematology (ASH) Annual Meeting takeda.com ↗ |
| 2020-07-30 | Takeda | Regulatory Takeda Announces U.S. FDA Breakthrough Therapy Designation Granted for Pevonedistat for the Treatment of Patients with Higher-Risk Myelodysplastic Syndromes (HR-MDS) takeda.com ↗
Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for its investigational drug pevonedistat for the treatment of patients with higher-risk myelodysplastic syndromes (HR-MDS). |
| 2020-05-29 | Takeda | Results Takeda Announces Compelling Data from the Phase 2 Trial of Pevonedistat Plus Azacitidine in Patients with Higher-Risk MDS takeda.com ↗
Pevonedistat Combination Demonstrates the Potential to Double Complete Remissions and Improve Outcomes in HR-MDS, With Safety Profile Similar to Azacitidine Alone |
All press releases naming this drug 4 releases
Evidence & citations 13 cited values
Every value below carries the sentence it was read from. 47 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pevonedistat | “Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes” PMID 25733005 ↗ Mar 201534“pevonedistat (also known as MLN4924) is the only NEDDylation inhibitor to date to enter phase III clinical trials.” PMID 41687727 ↗ Feb 2026 “Drug: Pevonedistat” NCT04172844 ↗ |
| Known as | MLN-4924 HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL1231160 ↗ |
| Known as | MLN-4924-003 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1231160 ↗ |
| Known as | MLN4924 | “A Phase 1/1b, Open-label Study of Pevonedistat (MLN4924, TAK-924) as Single Agent and in Combination With Azacitidine in Adult East Asian Patients With Acute Myeloid Leukemia...” NCT02782468 ↗10“A Phase II Study of Pevonedistat (MLN4924, TAK924) and Azacitidine as Maintenance Therapy After Allogeneic Stem Cell Transplantation for Non-Remission Acute Myelogenous Leukemia” NCT03709576 ↗ “Pevonedistat (TAK-924/MLN4924) is a novel inhibitor of NEDD8-activating enzyme (NAE) with single-agent activity in relapsed/refractory acute myeloid leukemia (AML).” PMID 29348128 ↗ Jan 2018 |
| Known as | PEVONEDISTAT (MLN4924) | ChEMBL registry synonym — accepted as the source's own label CHEMBL1231160 ↗ |
| Known as | PEVONEDISTAT HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL1231160 ↗ |
| Known as | TAK-924/MLN4924 | “The drug being tested in this study is called Pevonedistat (TAK-924/MLN4924).” NCT04985656 ↗ |
| Known as | TAK924 | “A Phase 1/1b, Open-label Study of Pevonedistat (MLN4924, TAK-924) as Single Agent and in Combination With Azacitidine in Adult East Asian Patients With Acute Myeloid Leukemia...” NCT02782468 ↗2“A Phase II Study of Pevonedistat (MLN4924, TAK924) and Azacitidine as Maintenance Therapy After Allogeneic Stem Cell Transplantation for Non-Remission Acute Myelogenous Leukemia” NCT03709576 ↗ “Pevonedistat (TAK-924/MLN4924) is a novel inhibitor of NEDD8-activating enzyme (NAE) with single-agent activity in relapsed/refractory acute myeloid leukemia (AML).” PMID 29348128 ↗ Jan 2018 |
| Known as | UNII-S3AZD8D215 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1231160 ↗ |
| Action | Inhibit | “a Novel Inhibitor of Nedd8-Activating Enzyme” NCT00677170 ↗ |
| Modality | Small molecule | “Pevonedistat, the first small-molecule inhibitor of NEDD8-activating enzyme” PMID 35545778 ↗ May 2022 |
| Route | Intravenous | “IV dose escalation for 5 consecutive days” NCT00677170 ↗ |
| Target | MCL1 | “Pevonedistat inhibits MCL1 through activation of NOXA” PMID 38572562 ↗ Sep 2024 |